RxDoctor Payments DataLook up a doctor →

Garry Brady, DO

General Practice · Rensselaer, INNPI 1457513764

Payments from drug & device makers

$5,620in general payments, 2019–2025

Across 349 payments — averaging $16.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Bayer$473
  • Otsuka America Pharmaceutical, Inc.$377
  • Lilly USA, LLC$293
  • AstraZeneca$291
  • Novo Nordisk$200
  • plus $2K from 41 others

What the payments were for

  • Food & beverage$5,56399%
  • Education$581%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,620 in reported general payments places this provider in the 95th percentile of 1,558 general practice providers in Indiana.

See all general practice providers in Indiana

Medicare billing

Part B allowed, 2024
$42,016
Medicare patients
162
Services billed
578

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase13$47,573
OzempicSemaglutide38$39,080
EliquisApixaban138$32,519
NuedextaDextromethorphan Hbr/Quinidine12$18,316
ZenpepLipase/Protease/Amylase15$18,168
TrulicityDulaglutide16$15,035
JardianceEmpagliflozin11$12,254
MyrbetriqMirabegron25$7,342
Breo ElliptaFluticasone/Vilanterol17$7,167
XareltoRivaroxaban18$6,261
Ivermectin18$4,916
Hydroxychloroquine Sulfate101$4,171
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr31$3,827
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen127$3,255
Autoshield Duo Pen NeedlePen Needle,dual Safety,diabetc29$3,095

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon$1,620$47,57313 claims
Novo NordiskOzempic$200$39,08038 claims
PfizerEliquis$87$32,519138 claims
Avanir Pharmaceuticals, Inc.Nuedexta$103$18,31612 claims
Aimmune Therapeutics, Inc.Zenpep$27$18,16815 claims
Lilly USA, LLCTrulicity$293$15,03516 claims
Boehringer IngelheimJardiance$47$12,25411 claims
Astellas Pharma US IncMyrbetriq$91$7,34225 claims
Johnson & JohnsonXarelto$172$6,26118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,558 general practice providers in Indiana.

Other general practice in Rensselaer

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →